Brickell Biotech, Inc.
(NASDAQ : BBI)

( )
BBI After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
MRKMerck & Co., Inc. -0.01%78.320.7%$1640.63m
JNJJohnson & Johnson 0.72%161.260.7%$1027.09m
PFEPfizer Inc. -0.38%41.510.9%$984.93m
ABBVAbbVie, Inc. 0.41%109.361.9%$719.23m
BMYBristol-Myers Squibb Co. 1.11%58.341.0%$691.66m
LLYEli Lilly & Co. 0.55%237.981.1%$629.67m
AZNAstraZeneca Plc 0.92%60.221.0%$377.08m
NVSNovartis AG 0.90%83.340.2%$177.37m
GSKGlaxoSmithKline Plc 0.75%39.010.2%$158.74m
RGENRepligen Corp. -0.61%266.926.8%$129.47m
AVIRAtea Pharmaceuticals, Inc. -2.89%39.280.3%$121.41m
CRVSCorvus Pharmaceuticals, Inc. -3.51%4.950.7%$109.87m
VTRSViatris, Inc. -0.15%13.460.0%$98.18m
NVONovo Nordisk A/S 1.89%102.340.1%$90.55m
RPRXRoyalty Pharma Plc 3.59%38.390.1%$87.06m

Company Profile

Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.